Industry Overview - The cannabis industry is evolving with renewed optimism as investors look toward 2026, with Canadian companies at the forefront of global expansion due to strong medical programs and increasing international demand [1][2] - Investors face challenges such as volatility, regulation, and changing consumer trends [1] Company Summaries Tilray Brands Inc. (TLRY) - Tilray is one of the largest cannabis and consumer wellness companies in Canada, operating in Canada, Europe, Latin America, and emerging medical markets [2] - The company does not own U.S. cannabis dispensaries but partners with licensed distributors, allowing for brand expansion while remaining compliant [2] - Recent financial performance shows gradual improvement, with revenue growth from both cannabis and beverage operations, although profitability remains challenging due to operating expenses and restructuring costs [4] - Investors are optimistic about potential catalysts such as expanding international medical programs and regulatory changes, but the stock may experience price swings [4] Cronos Group Inc. (CRON) - Cronos is a global cannabis and cannabinoid company focused on developing branded products for adult-use and medical markets, emphasizing quality and innovation [6] - The company collaborates with licensed partners instead of owning U.S. dispensaries, allowing for cautious growth while remaining compliant [6] - Financially, Cronos has reported steady revenue growth supported by strong demand for premium products, maintaining a solid balance sheet and improving gross margins [8] - Despite periodic net losses, the company's disciplined approach to growth appeals to investors seeking stability [8] Aurora Cannabis Inc. (ACB) - Aurora is a recognized cannabis producer in Canada, heavily involved in medical cannabis across multiple regulated markets [9] - The company focuses on export partnerships and compliant product channels instead of operating U.S. dispensaries [9] - Aurora's financial performance reflects a strategic shift toward profitability, with improved gross margins and reduced operating expenses [11] - The company has achieved positive adjusted earnings recently, indicating operational progress, and is expected to continue growth in international medical markets [11]

Core Insights - Cresco Labs (CRLBF) and other US multi-state operators (MSOs) experienced a decline last week as traders took profits following news of federal cannabis rescheduling, despite a preceding sector rally leading up to the announcement [1] Group 1 - The cannabis sector saw a rally prior to the federal cannabis rescheduling news [1] - Following the announcement, Cresco Labs and other US MSOs fell as traders capitalized on profits [1]

Group 1 - The Roundhill Cannabis ETF (WEED) has reached a 52-week high and is up 226.5% from its 52-week low of $8.79 per share [1][3] - The ETF is designed to provide investors with exposure to the cannabis sector [2] - Recent gains in cannabis stocks are attributed to President Trump's plans to ease federal marijuana regulations by reclassifying it from Schedule I to Schedule III, which has boosted investor optimism [3] Group 2 - The ETF may continue its strong performance in the near term, indicated by a positive weighted alpha of 43.48, suggesting potential for further rally [4]

Group 1 - The Roundhill Cannabis ETF (WEED) was launched in 2022 to provide investors with targeted access to companies in the cannabis and hemp industry [1] - The focus of the analysis is primarily on small- to mid-cap companies, which are often overlooked by many investors, while also occasionally considering large-cap companies for a broader market perspective [1]

Company Overview - Curaleaf Holdings, Inc. is a significant player in the U.S. cannabis industry, involved in the cultivation, manufacturing, and sale of cannabis and hemp products, including flowers, edibles, oils, and vape items [1] Market Focus - The company distributes its products through an extensive network of dispensaries, indicating a strong market presence and distribution capability [1] Research Approach - The analysis emphasizes a focus on small- to mid-cap companies, which are often overlooked by investors, while also occasionally reviewing large-cap companies to provide a comprehensive view of the equity markets [1]

Core Insights - The article discusses the launch of 420 Investor in 2013, coinciding with Colorado's legalization of cannabis for adult use, and its subsequent move to Seeking Alpha in 2023 [1] - The service has historically provided extensive coverage of the cannabis sector, including model portfolios, videos, and written materials aimed at educating investors about cannabis stocks [1] - The article expresses a negative outlook on the AdvisorShares Pure US Cannabis ETF (MSOS), highlighting its volatility and the challenges of making accurate predictions in such a fluctuating market [1] Company and Industry Overview - Alan Brochstein, a pioneer in cannabis investment analysis, founded AB Analytical Services in 2007 and has been a significant figure in the cannabis investment community since then [1] - Brochstein has managed the investing group 420 Investor, which focuses on 20 publicly-traded cannabis stocks, providing timely investment news, earnings previews, and post-report analyses [1] - The investing group features a model portfolio, 10 weekly videos with chart analysis, three weekly summary pieces, a monthly newsletter, and a chat function for investor inquiries [1]

Industry Overview - The U.S. cannabis industry is experiencing steady growth, with the legal market generating over $34 billion in annual sales and projections estimating it could reach $60 billion by 2030 due to increased state adoption and product demand [1] - Recent federal discussions on banking reform have positively impacted sector sentiment, as lawmakers are revisiting proposals to ease financial restrictions on licensed operators [1] Company Highlights Trulieve Cannabis Corp. (TCNNF) - Trulieve is a leading multi-state operator with over 200 dispensaries nationwide, primarily in Florida, where it has the largest retail presence [3][6] - The company reported quarterly revenue of approximately $288 million with a gross margin near 59 percent, and year-to-date cash flow from operations exceeded $200 million [6] - Trulieve's focus on improving margins and controlling costs has positioned it as a market leader, despite facing challenges such as heavy tax burdens [6] Cresco Labs Inc. (CRLBF) - Cresco operates over 70 Sunnyside dispensaries across key states and has a strong wholesale platform for branded product distribution [7][9] - The company reported quarterly revenue of nearly $165 million, showing steady growth, and has improved adjusted EBITDA margins through tighter cost controls [9] - Despite posting a net loss due to high interest expenses, Cresco's ability to maintain market share during industry consolidation is a significant strength [9] Verano Holdings Corp. (VRNOF) - Verano operates more than 150 dispensaries, with a strong presence in Florida and other high-value states like New Jersey and Illinois [10][12] - The company achieved quarterly revenue of roughly $203 million, maintaining year-over-year stability, although it faced net losses due to impairment charges [12] - Verano's adjusted EBITDA exceeded $50 million, indicating strong internal financial discipline and a focus on efficiency [12]

Core Insights - The U.S. cannabis market is evolving with legislative discussions, consumer trends, and business developments shaping its momentum, leading to increased investor interest in companies showing signs of stabilization and long-term growth potential [1][12] - November 2025 highlights several cannabis companies that are focusing on profitability, product line expansion, and positioning for future U.S. federal reform, despite ongoing market volatility [1][12] Company Summaries Tilray Brands Inc. (TLRY) - Tilray is a global cannabis lifestyle and consumer goods company with a significant presence in North America, expanding into beverages and wellness products, which strengthens its distribution footprint [2][4] - The company reported noticeable revenue growth year-over-year, driven by stronger consumer adoption and improved product placement, although it still operates at a net loss due to restructuring and long-term investments [5][4] - Tilray's diversification strategy provides stability during slower periods in the cannabis cycle, making it a notable candidate for investment in November [5][12] Canopy Growth Corporation (CGC) - Canopy Growth is a recognized name in the cannabis sector, repositioning itself for future U.S. opportunities through a leaner operational model and strategic pathways into the American market [6][8] - The company has shown modest revenue improvement alongside significant cost reductions, with year-over-year growth in both medical and adult-use markets [8][6] - Canopy's focus on operational discipline and strategic realignment positions it well for potential benefits if regulatory conditions shift [8][12] Cronos Group Inc. (CRON) - Cronos operates as a global cannabis and cannabinoid-innovation company, focusing on premium branded products and international expansion rather than a wide footprint of U.S. dispensaries [9][11] - The company has demonstrated solid revenue growth, reflecting rising consumer demand, although it operates at a loss due to research spending and expansion efforts [11][9] - Cronos maintains a strong cash position relative to its size, providing flexibility during uncertain periods, making it an appealing option for investors seeking growth potential beyond direct U.S. retail expansion [11][12]

Core Viewpoint - The potential reclassification of marijuana from Schedule I to Schedule III by the Trump administration could significantly impact the cannabis industry, unlocking new investment opportunities and tax benefits while also facilitating research on marijuana [4][5][22]. Group 1: Economic Impact - Reclassification could lead to billions in untapped potential in the hemp industry, positively affecting the U.S. economy and stock market [4]. - Cannabis businesses would gain access to major tax breaks, allowing them to deduct normal business expenses, which could result in significant tax savings [3]. - The reclassification may help normalize the cannabis industry in the eyes of mainstream investors, potentially increasing investment interest [2][12]. Group 2: Research Opportunities - The change would simplify federally approved research on marijuana, enabling scientists to explore new use cases and markets [2][22]. - Currently, research on Schedule I drugs is highly restricted, limiting the ability of companies to innovate within the cannabis sector [2][6]. Group 3: Market Sentiment and Trends - Support for cannabis legalization has grown, with approximately 64% of Americans favoring legalization, although this is a slight decrease from 68% in 2024 [11]. - The cannabis industry is characterized by volatility, with stocks often experiencing significant price swings in response to policy news [13][22]. Group 4: Investment Considerations - Investors should carefully consider their exposure level, as different types of cannabis stocks (growers, dispensaries, ETFs, pharmaceutical companies) come with varying risk and growth potential [18]. - The cannabis industry remains emerging and risky, with the timeline for federal legalization or banking reform still uncertain [22].

Industry Overview - The cannabis industry has experienced significant growth, with marijuana usage evolving over the years, leading to increased investment opportunities [1][3] - The volatility in marijuana stocks remains high, making it challenging for investors to realize sustainable profits [2][3] Company Highlights Cresco Labs Inc. - Cresco Labs reported a strong Q3 2025, maintaining market dominance and unlocking new growth opportunities [5] - Key financial metrics for Q3 2025 include: - Revenue of $165 million - Operating cash flow of $6 million - Gross profit of $79 million - Adjusted gross profit of $80 million with an adjusted gross margin of 48.8% - SG&A expenses of $52 million, representing 31.3% of revenue - Net loss of $22 million, which includes a $16 million loss from debt extinguishment and $2 million in non-cash impairment charges - Adjusted EBITDA of $40 million with an adjusted EBITDA margin of 24.1% [8] Trulieve Cannabis Corp. - Trulieve operates as a cannabis retailer, cultivating, processing, and distributing cannabis products [9] - On November 4th, Trulieve announced a notice of redemption for all US$368 million of its 8.0% senior secured notes due 2026, which will be delisted from the Canadian Securities Exchange [11] Verano Holdings Corp. - Verano operates as a vertically integrated multi-state cannabis operator in the U.S. [11] - On November 6th, Verano announced an exclusive partnership with Raw Gardens, allowing it to sell Raw Garden-branded products in New Jersey [12]